+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Esophageal Cancer Market by End User (Ambulatory Surgical Centers, Hospitals, Specialty Clinics), Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma), Disease Stage, Treatment Type - Global Forecast 2025-2030- Product Image
Esophageal Cancer Market by End User (Ambulatory Surgical Centers, Hospitals, Specialty Clinics), Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma), Disease Stage, Treatment Type - Global Forecast 2025-2030- Product Image
Sale

Esophageal Cancer Market by End User (Ambulatory Surgical Centers, Hospitals, Specialty Clinics), Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma), Disease Stage, Treatment Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967803
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The esophageal cancer market is evolving rapidly, impacted by shifting clinical practices, technology integration, and complex global dynamics. Senior healthcare and industry leaders require a holistic view of segmentation, innovation, and policy pressures to align operations and investments with emerging opportunities.

Market Snapshot: Esophageal Cancer Market Size and Growth

The Esophageal Cancer Market grew from USD 16.08 billion in 2024 to USD 17.45 billion in 2025 and is expected to expand at a CAGR of 8.33%, reaching USD 26.01 billion by 2030. This robust growth reflects increased adoption of advanced therapeutics, evolving epidemiology, and policy-driven shifts across mature and emerging markets. Market expansion is shaped by evolving treatment regimens, technological advances in diagnostics, and a growing focus on value-based care.

Scope & Segmentation of the Esophageal Cancer Market

This report delivers a comprehensive analysis across critical dimensions of the global esophageal cancer landscape, with deep dives into care delivery, treatment approaches, and geographic profiles.

  • End User Settings: Ambulatory surgical centers, hospital networks, and specialty clinics, each providing distinct procedural and follow-up capabilities.
  • Cancer Types: Adenocarcinoma and squamous cell carcinoma, each driven by unique risk factors, patient demographics, and screening needs.
  • Disease Stages: Stages I-IV, recognizing the influence of clinical presentation on treatment intensity and modality selection.
  • Treatment Modalities: Chemotherapy (including adjuvant, neoadjuvant, and palliative approaches), immunotherapy (such as cancer vaccines and checkpoint inhibitors), radiotherapy, surgery, and targeted therapies (EGFR, HER2, and VEGF inhibitors).
  • Regional Analysis: Coverage spans Americas (including in-depth U.S. state-level analysis), Europe, Middle East, Africa, and Asia-Pacific, capturing the diversity of regional infrastructures, policy initiatives, and epidemiologic challenges.
  • Key Industry Players: The competitive landscape profiles Merck & Co., Bristol-Myers Squibb, Roche, Johnson & Johnson, AstraZeneca, Pfizer, Novartis, Amgen, AbbVie, and Sanofi S.A., alongside emerging disruptors.

Innovative diagnostics—such as liquid biopsies and AI-powered imaging—are also addressed, highlighting their role in early detection and risk stratification.

Key Takeaways for Esophageal Cancer Market Stakeholders

  • Therapeutic innovation in immunotherapy and targeted agents is altering the clinical management paradigm, providing new options for complex cases and initiating changes in standard-of-care.
  • Diagnostic advances, including minimally invasive techniques and AI-driven imaging, support earlier and more precise disease characterization, which is vital for patient stratification and personalized treatment planning.
  • Disease segmentation, by type and stage, is central to guiding therapy selection and resource allocation. Hospitals and specialty centers each play distinct roles in comprehensive management and referral flows.
  • Collaboration between pharmaceutical, medtech, and digital health partners accelerates research, supports the co-development of therapies and diagnostics, and fosters integrated care pathways.
  • Real-world adoption of new technologies remains uneven, with disparities in patient access influenced by regional reimbursement frameworks and variable infrastructure investment.
  • Cross-border clinical collaborations and supply chain partnerships are increasingly shaping global response strategies and enabling harmonization of treatment guidelines.

Tariff Impact: Effects of 2025 United States Trade Measures

New U.S. tariffs introduced in 2025 on pharmaceutical ingredients and medical devices have generated added complexity for treatment supply chains. These fiscal changes prompt a reevaluation of sourcing strategies, motivate increased localization of production, and necessitate the implementation of new quality assurance and compliance protocols. Health providers report rising acquisition costs, resulting in reimbursement model reassessments and, in some cases, delays in therapy access. Strategic supply chain diversification and scenario planning are now critical for resilience and uninterrupted patient care.

Methodology & Data Sources

This report employs a multi-method approach, combining in-depth interviews with key opinion leaders and systematic secondary research. Data triangulation, scenario modeling, and expert validation support the integrity and impartiality of findings. Quality assurance protocols and ongoing advisory panel oversight ensure a rigorous research standard.

Why This Report Matters to Decision-Makers

  • Enables evidence-based strategic planning by integrating clinical, market, and policy insights specific to the esophageal cancer sector.
  • Identifies actionable opportunities across segments and regions, supporting robust investment and operational decision-making.
  • Equips executives with a clear framework to assess emerging risks, respond to policy changes, and strengthen market positioning.

Conclusion

Esophageal cancer market dynamics demand an agile, data-driven approach. This report empowers leaders to anticipate shifts, confidently support investment planning, and champion improved outcomes for patients worldwide.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of minimally invasive endoscopic ablation procedures for early-stage esophageal cancer improved patient outcomes
5.2. Integration of artificial intelligence algorithms in endoscopic screening to enhance early detection of esophageal lesions
5.3. Development of targeted immunotherapies addressing PD-1 and PD-L1 pathways for refractory esophageal carcinoma cases
5.4. Expansion of liquid biopsy techniques for monitoring circulating tumor DNA to guide personalized treatment strategies
5.5. Strategic partnerships between pharmaceutical companies and academic centers for novel esophageal cancer drug pipelines
5.6. Emergence of patient-centric care models combining telemedicine and wearable monitoring for post-surgery esophageal cancer survivors
5.7. Growth in reimbursement approvals for novel combination regimens incorporating chemotherapy and checkpoint inhibitors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Esophageal Cancer Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics
9. Esophageal Cancer Market, by Cancer Type
9.1. Introduction
9.2. Adenocarcinoma
9.3. Squamous Cell Carcinoma
10. Esophageal Cancer Market, by Disease Stage
10.1. Introduction
10.2. Stage I
10.3. Stage Ii
10.4. Stage Iii
10.5. Stage Iv
11. Esophageal Cancer Market, by Treatment Type
11.1. Introduction
11.2. Chemotherapy
11.2.1. Adjuvant Therapy
11.2.2. Neoadjuvant Therapy
11.2.3. Palliative Therapy
11.3. Immunotherapy
11.3.1. Cancer Vaccines
11.3.2. Checkpoint Inhibitors
11.4. Radiotherapy
11.5. Surgery
11.6. Targeted Therapy
11.6.1. Egfr Inhibitors
11.6.2. Her2 Inhibitors
11.6.3. Vegf Inhibitors
12. Americas Esophageal Cancer Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Esophageal Cancer Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Esophageal Cancer Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Bristol-Myers Squibb Company
15.3.3. Roche Holding AG
15.3.4. Johnson & Johnson
15.3.5. AstraZeneca PLC
15.3.6. Pfizer Inc.
15.3.7. Novartis AG
15.3.8. Amgen Inc.
15.3.9. AbbVie Inc.
15.3.10. Sanofi S.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ESOPHAGEAL CANCER MARKET: RESEARCHAI
FIGURE 24. ESOPHAGEAL CANCER MARKET: RESEARCHSTATISTICS
FIGURE 25. ESOPHAGEAL CANCER MARKET: RESEARCHCONTACTS
FIGURE 26. ESOPHAGEAL CANCER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 102. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 103. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 104. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 105. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 110. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 111. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 112. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 113. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 126. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 185. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 190. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 191. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 194. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 195. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 196. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 197. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 198. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 199. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 204. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 205. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 210. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 211. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 212. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 227. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 230. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 231. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 232. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 233. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 236. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 237. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 238. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 239. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 240. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 241. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 246. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 247. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 250. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 251. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 252. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 253. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 254. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 297. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 300. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 301. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 302. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 303. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 304. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 305. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 306. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 307. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 308. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 309. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 310. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 323. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 324. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 325. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 328. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 329. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 330. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 331. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 332. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 333. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 334. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 335. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 336. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 337. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 338. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 339. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 340. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 341. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 342. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
TABLE 343. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 344. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 345. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 346. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 347. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 348. FI

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Esophageal Cancer market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Johnson & Johnson
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 17.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 26.01 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Esophageal Cancer Drugs - Global Strategic Business Report - Product Image

Esophageal Cancer Drugs - Global Strategic Business Report

  • Report
  • 269 Pages
  • Global
From
Esophageal Cancer Market Report and Forecast 2025-2034 - Product Image

Esophageal Cancer Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Esophageal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Esophageal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Esophageal Cancer Market Report 2025 - Product Image

Esophageal Cancer Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Esophageal Cancer Drug Pipeline Analysis Report 2025 - Product Image

Esophageal Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Esophageal Cancer Drug Market

Esophageal cancer is a type of cancer that affects the esophagus, the tube that connects the throat to the stomach. Oncology drugs are used to treat this type of cancer, and the esophageal cancer drug market is a subset of the larger oncology drug market. These drugs are used to treat both early and advanced stages of the disease, and can include chemotherapy, targeted therapy, and immunotherapy. Esophageal cancer drugs are typically administered orally or intravenously, and can be used in combination with other treatments such as radiation therapy. The market for esophageal cancer drugs is expected to grow due to the increasing prevalence of the disease, as well as advances in drug development and delivery. Some companies in the esophageal cancer drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.